Mark Belletrutti

BSc, MSc, MD

Investigator and Pediatric Hematologist, BC Children's Hospital

Some individuals are born with a tendency to bleed without significant triggers. There are many new therapies emerging that can help these patients that need testing and evaluation of how well they work to improve bleeding problems in these individuals. I am interested in not only assessing how well they work but what the impact of better treatment has on these individuals’ daily lives.

Academic Affiliations

  • Clinical Associate Professor, Division of Hematology/Oncology/BMT, Department of Pediatrics, Faculty of Medicine, University of British Columbia
  • Research Theme: Childhood Diseases
  • Research Group(s): Childhood Cancer and Blood Research

Contact Information

Assistant

Carla Willems

cwillems@cw.bc.ca

Location

4480 Oak Street, Vancouver, British Columbia, Canada, V6H 3V4

Calling to Safeguard the Future of Classical Hematology

Pediatric Blood and Cancer

Pastore, Y.D. and Price, V. and Israels, S. and Chan, A.K.C. and Belletrutti, M. and Bruce, A. and Simpson, E. and Bowes, L. and Tole, S. and Sinha, R. and Brossard, J. and Malcomson, C. and Wheaton, L. and Rayar, M.

DOI: 10.1002/pbc.31740

Kids! We need to CHAT about clots and central lines

Journal of Thrombosis and Haemostasis

DOI: 10.1016/J.JTHA.2023.05.002

Management of children with hemophilia A on emicizumab who need surgery

Frontiers in Pediatrics

DOI: 10.3389/FPED.2023.1155853

Simoctocog alfa (Nuwiq) in previously untreated patients with severe haemophilia A-Final efficacy and safety results from the NuProtect study

European Journal of Haematology

DOI: 10.1111/EJH.14040

Long-term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia Awho had completed the NuProtect study in previously untreated patients

Haemophilia

DOI: 10.1111/HAE.14796

Mental health impacts of the COVID-19 pandemic on children with underlying health and disability issues, and their families and health care providers

Paediatrics & Child Health

DOI: 10.1093/PCH/PXAB103

The effects of the COVID-19 pandemic on the mental health of children with physical health problems or disabilities, families and health professionals

Paediatrics & Child Health

DOI: 10.1093/PCH/PXAC009

Quality of life in adolescents with heavy menstrual bleeding: Validation of the Adolescent Menstrual Bleeding Questionnaire (aMBQ)

Research and Practice in Thrombosis and Haemostasis

DOI: 10.1002/RTH2.12615

Measuring the impact of hemophilia on families: Development of the Hemophilia Family Impact Tool (H-FIT)

Research and Practice in Thrombosis and Haemostasis

Dover, S. and Young, N.L. and Blanchette, V.S. and Klaassen, R.J. and Chan, A.K. and Wakefield, C. and Bouskill, V. and Carcao, M. and Belletrutti, M. and Bruce, A.A.K. and Price, V.E.

DOI: 10.1002/rth2.12519

Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow-up retrospective analysis

Haemophilia

Carcao, M. and Shapiro, A. and Hwang, N. and Pipe, S. and Ahuja, S. and Lieuw, K. and Staber, J.M. and Belletrutti, M. and Sun, H.L. and Ding, H. and Wang, M. and Price, V. and Steele, M. and Tsao, E. and Feng, J. and Al-Khateeb, Z. and Dumont, J. and Jain, N.

DOI: 10.1111/hae.14192

Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study

Thrombosis and Haemostasis

Liesner, R.J. and Abraham, A. and Altisent, C. and Belletrutti, M.J. and Carcao, M. and Carvalho, M. and Chambost, H. and Chan, A.K.C. and Dubey, L. and Ducore, J. and Gattens, M. and Gresele, P. and Gruel, Y. and Guillet, B. and Jimenez-Yuste, V. and Kitanovski, L. and Klukowska, A. and Lohade, S. and Mancuso, M.E. and Oldenburg, J. and Pavlova, A. and Pollio, B. and Sigaud, M. and Vdovin, V. and Vilchevska, K. and Wu, J.K.M. and Jansen, M. and Belyanskaya, L. and Walter, O. and Knaub, S. and Neufeld, E.J.

DOI: 10.1055/s-0040-1722623

Updating the Canadian Hemophilia Outcomes"Kids Life Assessment Tool (CHO-KLAT) in the era of extended half-life clotting factor concentrates

Research and Practice in Thrombosis and Haemostasis

Price, V.E. and Dover, S. and Blanchette, V.S. and Klaassen, R.J. and Belletrutti, M. and Bruce, A.A.K. and Chan, A.K. and Wakefield, C. and Carcao, M. and Bouskill, V. and Young, N.L.

DOI: 10.1002/rth2.12498

The curious case of the bleeding twins: Neonatal bleeding secondary to acetylsalicylic acid prescribed for preeclampsia prevention

Paediatrics and Child Health (Canada)

Ediger, K. and Chok, R. and Belletrutti, M. and Hicks, M.

DOI: 10.1093/pch/pxaa091

Perceived Impacts of the COVID-19 Pandemic on Pediatric Care in Canada: A Roundtable Discussion

Global Pediatric Health

Nicholas, D.B. and Belletrutti, M. and Dimitropoulos, G. and Katz, S.L. and Rapoport, A. and Urschel, S. and West, L. and Zwaigenbaum, L.

DOI: 10.1177/2333794X20957652

Validation Study of the Heavy Menstrual Bleeding Questionnaire in Adolescents

Blood

DOI: 10.1182/BLOOD-2020-134545

Cold External Temperatures and Sickle Cell Morbidity in Children: A Retrospective Analysis

Journal of Pediatric Hematology/Oncology

Wachnian, C. and Tompkins, N. and Corriveau-Bourque, C. and Belletrutti, M. and Bruce, A.A.K.

DOI: 10.1097/MPH.0000000000001627

Engaging Fathers in Pediatric Palliative Care Research

Journal of Social Work in End-of-Life and Palliative Care

Nicholas, D. and Beaune, L. and Belletrutti, M. and Blumberg, J. and Ing, S. and Rapoport, A. and Barrera, M.

DOI: 10.1080/15524256.2019.1703877

Supplemental oxygen therapy recommendations in patients with sickle cell disease during air travel: A cross-sectional survey of North American health care providers

Paediatrics and Child Health (Canada)

Padda, A. and Corriveau-Bourque, C. and Belletrutti, M. and Bruce, A.A.K.

DOI: 10.1093/pch/pxz049

The Impact of Identifying the Syndromic and Genetic Diagnoses on Hematopoietic Stem Cell Transplantation Outcome in Patients with Inherited Bone Marrow Failure Syndromes

Blood

DOI: 10.1182/BLOOD-2019-121743

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review

Research and Practice in Thrombosis and Haemostasis

Yu, J.K. and Iorio, A. and Edginton, A.N. and Ahuja, S. and ?lvarez Romn, M.T. and Arrieta, M.E. and Arola, M. and Barillari, G. and Balasa, V. and Belletrutti, M. and Berrueco Moreno, R. and Beurrier, P. and Bidlingmaier, C. and Blanchette, V. and Blatny, J. and Bonanad, S. and Brose, K. and Brown, D. and Byant, P.C. and Canaro, M. and Carvalho, M. and Catarino, C. and Chitlur, M. and Cockrell, E. and Chowdary, P. and Cnossen, M. and Collins, P. and Coppens, M. and Croteau, S. and Cultrera, D. and de Cristofaro, R. and de Raucourt, E. and Desprez, D. and Dunn, A. and El-Ekiabi, M. and Faganel Kotnik, B. and Fischer, K. and Frotscher, B. and Garbiero, S. and Garrido Ruiz, R. and Gill, J. and Gomez del Castillo, C. and Gottstein, S. and Lassandro, G. and Giordano, P. and Hart, D. and Hegemann, I. and Hermans, C. and Hua, B. and Hwang, N. and Jackson, S. and James, P. and Katsarou, O. and Kavakli, K. and Kempton, C. and Kentouche, K. and Khan, O. and Kobelt, R. and Kruse-Jarres, R. and Laane, E. and Larson, E. and Lassila, R. and Lee, A. and Poon, M.-C. and Lissick, J. and Langstrom, S. and Mahlangu, J. and Makris, M. and Marchesini, E. and Mateo, J. and Marco Vera, P. and Martorell, M. and Matsushita, T. and McCrae, S. and Mignot-Castellano, E. and Montcrieff, C. and Maes, P. and Mondelars, V. and Bekart, M. and Mora, E. and Cristbal Morales, J. and Mourey, G. and Bertrand, M.A. and Napolitano, M. and Siragusa, S. and Negrier, C. and Neme, D. and Niinimaki, R. and Oldenburg, J. and Albert, T. and Ornstein, D. and Ozelo, M. and Panetta, J.C. and Neufeld, E.J. and P'Ng, S. and Peerlinck, K. and Pollio, B. and Poulard, C. and Gruel, Y. and Prezotti, A. and Price, V. and Primacakti, F. and Puyade, M. and Radossi, P. and Raffini, L. and Ragni, M. and Rangarajan, S. and Reding, M.T. and Reid, R. and Restrepo, J. and Ramirez, J. and Recht, M. and Rodriguez Lopez, M. and Ruiz-Sez, A. and Saleh, M. and Shapiro, A. and Sharathkumar, A. and Selmeczi, A. and Simpson, M. and Singleton, T. and Cruz, M.S. and Soto, V. and Steele, M. and Streif, W. and Sun, H.W. and Ritchie, B. and Sun, J. and Feng, X. and Suzuki, T. and Nagao, A. and Takemoto, C. and Tapp, H. and Teitel, J. and Tinmouth, A. and Thornburg, C. and Tosseto, A. and Turnstall, O. and Vezina, C. and Warren, B. and Wheeler, A. and Wilches Gutierrez, J.D. and Wu, J.K.M. and Wynn, T. and Yang, R. and Young, G. and Zanon, E. and Zupan, I.

DOI: 10.1002/rth2.12204

Impact of a nursing home support program for prophylactic factor administration in children with severe haemophilia

Haemophilia

Severe haemophilia A in a neonate presenting as haemopneumothorax after tracheo-oesophageal fistula-oesophageal atresia repair

BMJ Case Reports

Hung, Z. and Bahari, M. and Belletrutti, M.J. and Joynt, C.

DOI: 10.1136/bcr-2018-225526

DIAGNOSIS AND MANAGEMENT OF VON WILLEBRAND DISEASE TYPE 2B IN A PATIENT WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Pediatric Blood and Cancer

Blood coagulation dissected

Transfusion and Apheresis Science

Pryzdial, E.L.G. and Lee, F.M.H. and Lin, B.H. and Carter, R.L.R. and Tegegn, T.Z. and Belletrutti, M.J.

DOI: 10.1016/j.transci.2018.07.003

Safety and efficacy of multiple factor switches in a short time period in children with haemophilia A

Haemophilia

Immunogenicity, efficacy and safety of Nuwiq (human-cl rhFVIII) in previously untreated patients with severe haemophilia A"Interim results from the NuProtect Study

Haemophilia

Liesner, R.J. and Abashidze, M. and Aleinikova, O. and Altisent, C. and Belletrutti, M.J. and Borel-Derlon, A. and Carcao, M. and Chambost, H. and Chan, A.K.C. and Dubey, L. and Ducore, J. and Fouzia, N.A. and Gattens, M. and Gruel, Y. and Guillet, B. and Kavardakova, N. and El Khorassani, M. and Klukowska, A. and Lambert, T. and Lohade, S. and Sigaud, M. and Turea, V. and Wu, J.K.M. and Vdovin, V. and Pavlova, A. and Jansen, M. and Belyanskaya, L. and Walter, O. and Knaub, S. and Neufeld, E.J.

DOI: 10.1111/hae.13320

Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A withinhibitors"A retrospective analysis

Haemophilia

Carcao, M. and Shapiro, A. and Staber, J.M. and Hwang, N. and Druzgal, C. and Lieuw, K. and Belletrutti, M. and Thornburg, C.D. and Ahuja, S.P. and Morales-Arias, J. and Dumont, J. and Miyasato, G. and Tsao, E. and Jain, N. and Pipe, S.W.

DOI: 10.1111/hae.13413

The clinical impact of copy number variants in inherited bone marrow failure syndromes

npj Genomic Medicine

Waespe, N. and Dhanraj, S. and Wahala, M. and Tsangaris, E. and Enbar, T. and Zlateska, B. and Li, H. and Klaassen, R.J. and Fernandez, C.V. and Cuvelier, G.D.E. and Wu, J.K. and Pastore, Y.D. and Silva, M. and Lipton, J.H. and Brossard, J. and Michon, B. and Abish, S. and Steele, M. and Sinha, R. and Belletrutti, M.J. and Breakey, V.R. and Jardine, L. and Goodyear, L. and Kofler, L. and Cada, M. and Sung, L. and Shago, M. and Scherer, S.W. and Dror, Y.

DOI: 10.1038/s41525-017-0019-2

Supplemental Oxygen during Air Travel in Sickle Cell Disease - Common Clinical Practices

Blood

Re-Analysis of Next Generation Sequencing Gene Panel Data By Normalized Coverage Values Reveals Previously Undetected Copy Number Variations in Inherited Bone Marrow Failure Syndromes

Blood

Immune Tolerance Induction in Hemophilia A Patients Using Wilate (R) -a Canadian 10 Year Study (PREVAIL)

Blood

Surgery as a Recurrent Trigger for Immune Thrombocytopenia (ITP) in a Patient Cured of M7 Acute Myelogenous Leukemia

Journal of Pediatric Hematology/Oncology

Monfries, N. and Belletrutti, M. and McKillop, S.

DOI: 10.1097/MPH.0000000000000533

Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents: An open-label phase IIa study

Thrombosis and Haemostasis

Halton, J.M.L. and Lehr, T. and Cronin, L. and Lobmeyer, M.T. and Haertter, S. and Belletrutti, M. and Mitchell, L.G.

DOI: 10.1160/TH15-04-0275

Prophylaxis with factor-eight-inhibitor-by-passing-activity 3 days a week results in safe and effective haemostasis in children with haemophilia a with inhibitors

Journal of Thrombosis and Haemostasis

Examining the Experiences of Fathers of Children with a Life-Limiting Illness

Journal of Social Work in End-of-Life and Palliative Care

Nicholas, D.B. and Beaune, L. and Barrera, M. and Blumberg, J. and Belletrutti, M.

DOI: 10.1080/15524256.2016.1156601

Inhibitor Development in Previously Untreated Patients with Severe Hemophilia a Treated with Nuwiq, a New Generation Recombinant FVIII of Human Origin

Blood

DOI: 10.1182/BLOOD.V128.22.327.327

Hematology

Essentials for the Canadian Medical Licensing Exam

Belletrutti, M. and Liew, E.

Copy Number Variants Underlying Inherited Bone Marrow Failure Syndromes

Blood

Molecular Analysis of Diamond Blackfan Anemia and Genotype-Phenotype Correlation: Experience from the Canadian Inherited Marrow Failure Registry

Blood

DOI: 10.1182/BLOOD.V126.23.3621.3621

Adenovirus necrotizing hepatitis complicating atypical teratoid rhabdoid tumor

Pediatrics International

McKillop, S.J. and Belletrutti, M.J. and Lee, B.E. and Yap, J.Y. and Noga, M.L. and Desai, S.J. and Sergi, C.

DOI: 10.1111/ped.12674

The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes

Haematologica

Cada, M. and Segbefia, C.I. and Klaassen, R. and Fernandez, C.V. and Yanofsky, R.A. and Wu, J. and Pastore, Y. and Silva, M. and Lipton, J.H. and Brossard, J. and Michon, B. and Abish, S. and Steele, M. and Sinha, R. and Belletrutti, M. and Breakey, V. and Jardine, L. and Goodyear, L. and Sung, L. and Shago, M. and Beyene, J. and Sharma, P. and Zlateska, B. and Dror, Y.

DOI: 10.3324/haematol.2014.117457

Management and Outcome of Patients With Langerhans Cell Histiocytosis and Single-Bone CNS-Risk Lesions: A Multi-Institutional Retrospective Study

Pediatric Blood and Cancer

Chellapandian, D. and Shaikh, F. and van den Bos, C. and Somers, G.R. and Astigarraga, I. and Jubran, R. and Degar, B. and Carret, A.-S. and Mandel, K. and Belletrutti, M. and Dix, D. and Visser, J. and Abuhadra, N. and Chang, T. and Rollins, B. and Whitlock, J. and Weitzman, S. and Abla, O.

DOI: 10.1002/pbc.25645

Hemoglobin Constant Spring exhibits prolonged ex vivo stability when assessed by HPLC

Clinical Biochemistry

Estey, M.P. and Belletrutti, M. and Rodriguez-Capote, K. and Higgins, T.

DOI: 10.1016/j.clinbiochem.2015.03.021

Improving diagnostic precision, care and syndrome definitions using comprehensive next-generation sequencing for the inherited bone marrow failure syndromes

Journal of Medical Genetics

Ghemlas, I. and Li, H. and Zlateska, B. and Klaassen, R. and Fernandez, C.V. and Yanofsky, R.A. and Wu, J. and Pastore, Y. and Silva, M. and Lipton, J.H. and Brossard, J. and Michon, B. and Abish, S. and Steele, M. and Sinha, R. and Belletrutti, M. and Breakey, V.R. and Jardine, L. and Goodyear, L. and Sung, L. and Dhanraj, S. and Reble, E. and Wagner, A. and Beyene, J. and Ray, P. and Meyn, S. and Cada, M. and Dror, Y.

DOI: 10.1136/jmedgenet-2015-103270

MANAGEMENT AND OUTCOME OF PATIENTS WITH LANGERHANS CELL HISTIOCYTOSIS AND SINGLE-BONE CNS-RISK LESIONS: A MULTI-INSTITUTIONAL RETROSPECTIVE DESCRIPTIVE STUDY

Pediatric Blood and Cancer

HbM methaemoglobinaemia as a rare case of early neonatal benign cyanosis

BMJ Case Reports

Elboraee, M.S. and Clarke, G. and Belletrutti, M.J. and Escoredo, S.

DOI: 10.1136/bcr-2015-212336

Application of Novel Next Generation Sequencing Gene Panel Assay to Genetic and Clinical Diagnosis of Inherited Bone Marrow Failure Syndromes

Blood

DOI: 10.1182/BLOOD.V124.21.257.257

A Case Series Evaluating the Use of a Von Willebrand Factor/Factor VIII Concentrate (Wilate r) for Immune Tolerance Induction (ITI) in Children with Severe Factor VIII Deficiency

Blood

Risk Factors for Poor Survival after Hematopoietic Stem Cell Transplantation in Inherited Bone Marrow Failure Syndromes

Blood

UNDERSTANDING THE EXPERIENCES AND SUPPORT NEEDS OF FATHERS OF CHILDREN WITH LIFE-LIMITING ILLNESSES

Pediatric Blood and Cancer

Use of gemcitabine with multi-stage surgical resection as successful second-line treatment of metastatic pancreatoblastoma

Journal of Pediatric Hematology/Oncology

Belletrutti, M.J. and Bigam, D. and Bhargava, R. and Grundy, P.

DOI: 10.1097/MPH.0b013e3182707577

Central venous catheter sampling of low molecular heparin levels: An approach to increasing result reliability

Pediatric Critical Care Medicine

Bauman, M.E. and Belletrutti, M. and Bauman, M.L. and Massicotte, M.P.

DOI: 10.1097/PCC.0b013e31820ac2f6

LANGERHANS CELL HISTIOCYTOSIS PRESENTING AS AN ISOLATED LUNG LESION IN A NEWBORN MALE

Pediatric Blood and Cancer

Typhlitis in children with malignancy: A single center experience

Journal of Pediatric Hematology/Oncology

El-Matary, W. and Soleimani, M. and Spady, D. and Belletrutti, M.

DOI: 10.1097/MPH.0b013e3181eda606

Novel uses of insulin syringes to reduce dosing errors: A retrospective chart review of enoxaparin whole milligram dosing

Thrombosis Research

Bauman, M.E. and Black, K.L. and Bauman, M.L. and Belletrutti, M. and Bajzar, L. and Massicotte, M.P.

DOI: 10.1016/j.thromres.2008.09.001

Evaluation of enoxaparin dosing requirements in infants and children Better dosing to achieve therapeutic levels

Thrombosis and Haemostasis

DOI: 10.1160/TH08-03-0148

A "living" will

Canadian Medical Association Journal

M. Belletrutti and I. DeKock

DOI: 10.1503/cmaj.080111

03 / 2008

The language of living wills: Reply

Canadian Medical Association Journal

DOI: 10.1503/CMAJ.1080040

Chronic immune thrombocytopenic-purpura in children - A survey of the Canadian experience

Journal of Pediatric Hematology/Oncology

DOI: 10.1097/MPH.0B013E3180320B36

Does increasing the starting dose of enoxaparin result in better-treatment of children requiring thromboprophylaxis? A retrospective cohort study

Pediatric Blood and Cancer

HAVEN7: A Phase IIIb, Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Patients from Birth to 12 Months of Age with Hemophilia A without Inhibitors

Hemophilia is a hereditary disorder in which patients suffer from blood clotting impairment. Patients with hemophilia have a deficiency of a blood protein, a ‘clotting factor’. There are two types of hemophilia: hemophilia A and hemophilia B. Hemophilia A is the most prevalent and is characterized by a deficiency of the blood clotting factor, factor VIII (FVIII). Hemophilia A can be sub-divided into three different types based on plasma concentrations of FVIII: severe, with concentrations of <1 international unit (IU) dL-1; moderate with 1-5 IU dL-1; and mild with FVIII concentrations >5 IU dL-1.

The purpose of this study is to describe the experience of newborns and infants (aged less than or equal to 1 year of age) with severe hemophilia A when they receive emicizumab treatment for 1 year. It is also to evaluate whether they experience any good or bad effects with emicizumab. After 1 year of treatment, children in this study will continue to receive emicizumab and will be monitored for an additional 7 years as part of this study. The purpose is to learn how emicizumab works in children with hemophilia A as they grow and develop, and to check the health of their joints over time. A total of about 50 children at ~20 sites globally will take part in this study (about 20 children younger than 3 months of age and 30 children from 3 months to 12 months of age at the time of enrolment). It is anticipated that about 1 - 2 children will participate in this study at B.C. Children’s Hospital.

Prospective study of experience with Bayer’s recombinant factor VIII (rFVIII) concentrate, Kovaltry, in persons with hemophilia A followed in Comprehensive Care Hemophilia Programs in Canada

Hemophilia A affects approximately 3,000 Canadians, of which approximately 30% exhibit the severe phenotype and approximately 10% exhibit the moderate phenotype. Patients with severe hemophilia experience spontaneous and trauma-induced bleeds. Bleeding into joints initiates a sequence of events that can culminate in disabling arthropathy. Clotting factor replacement therapy, administered either ‘on demand’ following acute bleeding episodes or prophylactically, is the mainstay for treatment of hemophilia. In clinical practice, FVIII doses are typically calculated based on body weight and rounded to the nearest vial size. Recent research has demonstrated the benefit of further tailoring a person’s factor dose based on their pharmacokinetic profile but this has traditionally required blood sampling at multiple time-points (6-10 samples) and sophisticated software to analyze. Recently, a more efficient sampling combined with newly developed software that uses a population PK model (estimates individual PK parameters based upon PK measurements of a large population and variables such as age and weight) has shown to be reliable and only required 2-4 blood draws.

This study aims to assess the predictive accuracy of a 2-point, single clinic visit PK sampling protocol with no washout (48 h ± 4 h and 3h ± 30 min) with a 3-point, 2 clinic visits PK sampling protocol with no washout (48 h ± 4 h, 3 h ± 30 min and 24 h ± 4 h) that is known to have minimal error for the PK parameter of terminal half-life. Patients age 0-18 years receiving Kovaltry, one of the Factor VIII replacement products will be assessed.

Exploring the psychosocial and health service consequences of Coronavirus on children and their families: Lessons learned for pediatric health care practice and policy

Building on past experience studying child and family impacts in the context of SARS, I am part of a pan-Canadian research team, with the help of CIHR funding, that is examining child and family impacts of COVID across several conditions, including cardiac transplantation and congenital heart lesions, chronic respiratory conditions, sickle cell disease, end-of-life conditions, and autism. We have published an initial roundtable discussion of clinicians during the early phase of the pandemic and are continuing to recruit and interview patients, families, and clinicians as this pandemic continues to evolve.

Grants

"Exploring the psychosocial and health service consequences of Coronavirus on children and their families: Lessons learned for pediatric health care practice and policy". Principal Investigator: D. Nicholas. Co-Investigators: M. Belletrutti, S. Katz, A. Rapaport, S. Urschel, L.J. West. Funding Source: Canadian Institutes of Health Research Operating Grant ($261,367) – 2 years, 2020-2022

"TIPS for Trainees: Understanding when to test for Thrombophilia in Pediatrics". Principal Investigator: A. Bruce. Co-Investigators: M. Belletrutti, C. Corriveau-Bourque. Funding Source: Canadian Pediatric Thrombosis and Hemostasis Network ($12,000) – 2 years, 2019-2021

"Bleeding in adolescent females on antiepileptic medications". Principal Investigator: C. Corriveau-Bourque. Co-Investigators: J. Kassiri, M. Belletrutti, A. Bruce. Funding Source: Canadian Pediatric Thrombosis and Hemostasis Network ($12,000) – 2 years, 2018-2021

Related News

Every day, our researchers work towards breakthroughs to transform the lives of kids in BC and around the world. Learn about our latest innovations and advancements in child health.

Our Research

At BC Children’s, we are making discoveries that save lives and transform health care for children in our province and around the world. Our research portfolio includes basic, clinical, population, and public health research.

EXPLORE OUR RESEARCH

Stay in the Know

Sign up for compelling stories about innovative science, the doctors and researchers who turn ideas into discoveries and treatments, and the kids and families whose lives are changed.

This field is for validation purposes and should be left unchanged.